Espiro

Quick links to important sections

Espiro

Selected form

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Espiro

Quick Facts

Property Description
Active ingredient Eplerenone
Form Oral film-coated tablet
Pharmacological class Selective Aldosterone Antagonist (SAA)
Common use Cardiovascular support
Origin Synthetic

Espiro: Defining the Selective Aldosterone Antagonist

Espiro is a synthetic, prescription-only medication containing the sole active ingredient, Eplerenone. It is classified as a Selective Aldosterone Antagonist (SAA), which is a specialized form of Mineralocorticoid Receptor Antagonist (MRA). This classification confirms the drug's fundamental mechanism involves intervening in the effects of the aldosterone hormone within the body's systems that regulate fluid and blood pressure. Eplerenone is structurally distinguished from older MRAs, such as Spironolactone, by its high degree of selectivity for the mineralocorticoid receptor, a feature that is clinically recognized for optimizing the blockade of aldosterone with fewer interactions with other hormone pathways.

Composition, Form, and General Purpose

The medication is available as an oral film-coated tablet and is administered exclusively by mouth, consistent with its design as a single-ingredient product. Eplerenone's chemical structure confirms its synthetic origin as a steroidal derivative. The general purpose of Espiro is to provide targeted cardiovascular support by adjusting the body's fluid and electrolyte balance. By selectively blocking aldosterone, the drug helps the kidneys excrete excess sodium and water. This selective action reduces the volume of fluid circulating in the body, which helps to decrease the physical workload on the heart. Importantly, Eplerenone functions as a potassium-sparing diuretic, aiding in the removal of fluid while minimizing the depletion of the vital mineral potassium, a key consideration in the long-term management of chronic cardiovascular conditions.

Regulatory References

  1. Eplerenone Drug Information (MedlinePlus)

What side effects are possible with Espiro?

Possible Side Effects and Safety Information

The official safety documentation for Espiro (Eplerenone) focuses on the drug's potential effects as a Selective Aldosterone Antagonist. The most clinically significant safety concern documented by regulatory authorities (such as the FDA and EMA) is the risk of Hyperkalemia, or high potassium levels in the blood.

Hyperkalemia is classified as a principal adverse reaction, and if it becomes severe ( serum potassium > 5.5 mEq/L), it may lead to serious, life-threatening cardiac rhythm disturbances. The risk of this event is officially stated to be highest within the first three months of starting treatment or following a dose adjustment, requiring mandatory monitoring of serum potassium and creatinine.


Adverse Reactions by Frequency and System

Adverse reactions are classified based on incidence in clinical trials:

  • Common Reactions (often observed): These include dizziness, diarrhea, coughing, and fatigue. Gastrointestinal issues, along with neurological effects and general disorders, are the most frequently reported System-Organ Classes.
  • Uncommon Reactions (less often observed): These include gynecomastia (breast enlargement/tenderness), skin rash, and hypotension (low blood pressure).

Safety Constraints and Special Populations

Regulatory documents establish clear limits for the use of Espiro:

  • Contraindications: The medicine must not be started if a patient has a baseline serum potassium level >5.0 mEq/L or has severe pre-existing renal insufficiency or severe hepatic insufficiency. Concomitant use with other potassium-sparing diuretics is also contraindicated due to hyperkalemia risk.
  • Geriatric Patients: The official label notes that older adults (ge 65 years) may face an increased risk of hyperkalemia due to age-related decline in kidney function.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — Official Regulatory Information for Espiro

Overdose Scope

Element Official Regulatory Description
Documented overdose presentations The most likely manifestations are Hypotension (low blood pressure) and Hyperkalemia (elevated serum potassium levels). Symptoms may include dizziness, fainting, nausea, and vomiting [Multiple Government Sources].
Physiological systems affected (as stated in label) Primarily the Cardiovascular system (Hypotension, cardiac rhythm changes) and Electrolyte/Fluid balance (Hyperkalemia) [Multiple Government Sources].
Dose-related or exposure-related factors (if applicable) Overdose is associated with exposure to excessive doses of the medication.
Population-specific overdose notes (if applicable) Increased risk of hyperkalemia and overdose severity is associated with pre-existing impaired renal function [FDA AccessData].
Emergency-response statements (as written in official documents) No specific antidote is known. Management consists of symptomatic and supportive treatment [NIH NCBI StatPearls].
When immediate medical help is required (label-derived phrasing only) Seek immediate medical attention or contact a Poison Control center. Emergency services must be contacted if the individual has collapsed, is experiencing trouble breathing, or cannot be awakened [NIH MedlinePlus].

Overdose Classifications (High-Level)

Element Official Regulatory Description (Source-Derived)
Severity classification (as defined in official documents) Overdose can lead to life-threatening cardiac arrhythmias and acute loss of consciousness [NIH MedlinePlus].
Regulatory basis (EMA / FDA / etc.) Information derived from FDA Prescribing Information, NIH MedlinePlus, and EMA-aligned documents [Multiple Government Sources].
Overdose-context constraints (as defined in official documents) Management requires close patient monitoring; the drug is not efficiently removed by hemodialysis [NIH NCBI StatPearls].

Resulting Overdose Structure

Official overdose statements:

  • Overdose primarily manifests as hypotension and hyperkalemia, with associated signs like dizziness and fainting.
  • The most serious risk is the development of cardiac arrhythmias resulting from severe hyperkalemia.
  • No specific antidote is known; treatment is limited to symptomatic and supportive management.
  • Immediate medical attention must be sought, and the patient requires close monitoring of vital signs and serum potassium levels.
  • Individuals with impaired renal function are noted to have a heightened risk of overdose severity.

Connection to the overall overdose profile

Regulatory documents define the overdose profile based on the physiological risks of severe electrolyte imbalance (hyperkalemia) and volume depletion (hypotension). These official statements directly establish the need for immediate medical attention and mandatory supportive care, particularly the management of high potassium levels, which poses the greatest threat for life-threatening complications.

Therapeutic Uses of Espiro

Quick Facts: Uses of Espiro

  • High Blood Pressure (Hypertension)
  • Heart Failure (Reduced ejection fraction)
  • Fluid Retention (Edema) associated with liver or kidney conditions
  • Low Potassium Levels (Hypokalemia)
  • Excess Aldosterone (Primary Hyperaldosteronism)

What Espiro Treats: Main Uses and Benefits

Espiro is a prescription medication utilized to support the management of certain chronic cardiovascular and fluid-balance conditions. It is used alone or in combination with other therapeutic options to help control high blood pressure (hypertension). Controlling blood pressure is an essential part of comprehensive cardiovascular risk management.

Additionally, this drug is an important component of the treatment regimen for individuals with heart failure, specifically heart failure with reduced ejection fraction. In this setting, the medication is intended to provide support for the heart muscle and assist in the management of associated fluid retention.

Espiro is also prescribed to address edema (fluid retention) that may be associated with variousconditions, including liver cirrhosis or nephrotic syndrome, when fluid and sodium restriction alone are not adequate. It may be used for managing low potassium levels and for diagnosing or treating conditions involving excess production of the hormone aldosterone.

Eligibility and Restrictions for Use

This section summarizes the official population eligibility and non-eligibility rules for Espiro (spironolactone) based on governmental regulatory documents.

Official Eligibility Restrictions

Espiro Must Not Be Used (Contraindications):

The medicine is strictly contraindicated in several patient populations, meaning it must not be used under any circumstances due to significant safety risks. These include individuals with:

  • Hyperkalemia (abnormally high blood potassium levels).
  • Addison's disease (uncontrolled adrenal insufficiency).
  • Acute renal insufficiency, anuria (failure to produce urine), or significant impairment of renal excretory function (moderate to severe chronic renal impairment).
  • Known hypersensitivity (allergy) to spironolactone or any component of the formulation.
  • Concomitant use of eplerenone (another potassium-sparing diuretic).

Restricted or Special Consideration Populations:

  • Pediatric Use: Use in children is restricted and should be carried out under the guidance of a pediatric specialist and is contraindicated in those with moderate to severe renal impairment.
  • Geriatric Use: Caution is required; treatment should be started at the lowest possible dose due to the increased likelihood of age-related renal dysfunction.
  • Pregnancy/Lactation: Use during pregnancy is generally not recommended and is only considered if the benefit outweighs the risk. A decision to discontinue nursing or discontinue the drug is required during lactation.

What should I know about interactions with other medicines?

Espiro Interactions with other medicines and products


The official interaction profile of Espiro (Eplerenone) is primarily governed by its metabolism via the CYP3A4 enzyme and its potassium-sparing pharmacodynamic action, as documented by regulatory authorities.

Co-administration is contraindicated with Strong CYP3A4 Inhibitors, such as ketoconazole or ritonavir, as these agents significantly increase Eplerenone plasma concentrations. Concomitant use with Potassium Supplements or other Potassium-Sparing Diuretics (e.g., spironolactone, amiloride) is also formally prohibited due to the severe risk of hyperkalemia. Furthermore, the triple combination of Eplerenone with an ACE Inhibitor and an Angiotensin II Receptor Blocker (ARB) is restricted.

Interactions requiring caution include co-administration with Moderate CYP3A4 Inhibitors (e.g., erythromycin, verapamil), which are documented to increase Eplerenone exposure. Strong inducers of the enzyme, such as the herbal product St. John's Wort, are not recommended as they decrease exposure.

A heightened risk of hyperkalemia exists when Eplerenone is combined with ACE Inhibitors, ARBs, NSAIDs, or Trimethoprim. Grapefruit Juice and Potassium-Containing Salt Substitutes must be avoided as they affect exposure or electrolyte balance. Regulatory data indicate that the risk of hyperkalemia with interacting agents is greater in specific populations, including the elderly and patients with impaired renal function, and that Eplerenone exposure is increased in those with moderate hepatic impairment.

Mechanism of Action

How Espiro Works: Mechanism of Action


Blocking the Aldosterone Receptor

The primary action of Espiro involves its molecule and active metabolites acting as competitive antagonists at the Mineralocorticoid Receptor (MR). This blockade prevents the hormone aldosterone from binding, thereby directly inhibiting the gene regulation that controls the movement of sodium ( Na^+) and potassium ( K^+) in the kidney. This molecular event regulates the body's fluid and electrolyte homeostasis.


Modulating Fluid Volume and Systemic Pressure

The blockage of the MR in the kidney leads to a cascade that results in the excretion of sodium and water while causing the body to retain potassium. This decrease in the overall circulating fluid volume is a key physiological consequence, as it contributes to a reduction in systemic vascular pressure. The mechanism also involves the dampening of aldosterone-mediated pro-fibrotic signaling in cardiovascular tissue, modulating aldosterone-driven signaling cascades that impact cardiac and vascular tissue structure.


Anti-Androgen Receptor Interference

The drug has an auxiliary mechanistic domain involving binding and antagonism at the Androgen Receptor (AR), found in many non-renal tissues. This off-target interaction with the AR results in attenuated androgen signaling within responsive tissues. This activity is separate from the primary fluid and electrolyte regulation and contributes to the drug's full profile of hormonal and physiological modulation.

Dosage and Administration Information

Administration Guidelines for Espiro

The official instructions for Espiro (which may be marketed under various trade names and formulations) establish a structured regimen for its use. The route of administration is oral, available in a suspension or tablet form, and the medication is taken once daily or in divided doses as prescribed by a healthcare provider.

Official Administration Rules

Administration Aspect Guideline
Route & Frequency Oral (Suspension or Tablet), typically once daily.
Preparation If using the oral suspension, the bottle must be shaken well before each measured dose. Use a marked measuring device (spoon, syringe, or cup) for accurate dosing.
Timing (Meals) May be taken with or without food. However, it is mandatory to follow a consistent approach (e.g., always with food or always without food) each day.
Missed Dose Take the missed dose as soon as it is remembered. If it is almost time for the next scheduled dose, skip the missed dose and resume the regular schedule. Do not take a double dose to make up for the missed one.
Age-Specific Dosage for children must be carefully determined by the prescriber; use in the pediatric population requires professional assessment.

Procedural Steps

  1. Obtain the exact prescribed dosage form and strength (tablet or suspension).
  2. Shake the suspension bottle well before measuring.
  3. Measure the dose precisely using a calibrated device.
  4. Ingest the dose orally, maintaining consistency with the established meal timing routine.
  5. Adhere strictly to the once-daily or divided dosing schedule as instructed by the healthcare provider.

This protocol ensures the medication is delivered according to its specifications for maximum consistency and safety.

Recent Clinical Evidence

The clinical evidence describing Espiro (Eplerenone) is derived primarily from large-scale, controlled clinical trials, which compare the medication to a placebo (an inactive substance) or an active comparator. Research examined the outcomes and patterns observed in defined groups of patients with specific cardiovascular conditions.

Evidence for Heart Failure Following a Heart Attack

Researchers explored the use of Espiro in adults who experienced an acute myocardial infarction (MI) and showed signs of left ventricular dysfunction. The research examined outcomes including the occurrence of all-cause mortality, cardiovascular mortality, and the frequency of hospitalization for heart failure. The main trial, considered High-level evidence, reported measurements that included a lower number of events for the composite outcome of mortality or cardiovascular hospitalization in the Eplerenone group compared to the placebo group. Data for patients with certain severe baseline conditions, such as high serum potassium or markedly impaired renal function, were not characterized, as these patients were excluded from the primary research.

Evidence for Chronic Heart Failure with Mild Symptoms

Research has explored the use of Espiro in patients with milder, chronic systolic heart failure (HFrEF) and mild symptoms. The pivotal, placebo-controlled trial monitored outcomes such as cardiovascular death or first hospitalization for heart failure. The study reported a lower number of events for this composite endpoint in the study group compared to placebo. Due to the early termination of this trial, the full, natural-course long-term data beyond approximately 21 months are not fully established from that specific study.

Evidence for High Blood Pressure (Hypertension)

Research for high blood pressure involved short-term, controlled trials primarily focused on adults with mild-to-moderate essential hypertension. The primary measurements monitored were changes in seated Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) over time. The trials reported that the treatment groups had lower SBP and DBP measurements compared to the placebo group. However, these follow-up durations were limited (typically 6 to 24 weeks), and dedicated large-scale studies using long-term outcomes like stroke or mortality as the primary endpoint are not available for this specific indication.

Frequently Asked Questions (FAQ)

Common questions about Espiro (FAQ)

Q: Is Espiro a steroid?

A: Espiro's active ingredient, eplerenone, is chemically derived from the steroid class of compounds. However, it is classified as a selective aldosterone antagonist, which means it targets a specific hormone receptor.


Q: How does Espiro help with breathing?

A: Espiro is not indicated for treating breathing problems. Its primary uses are for cardiovascular conditions. The official adverse reaction list for this medication does, however, include shortness of breath.


Q: What are the most common conditions Espiro is prescribed for?

A: Official information indicates Espiro is prescribed for two main purposes: to help reduce the risk of cardiovascular events, including death, in stable adult patients who have experienced a heart attack and have symptomatic heart failure; and for the treatment of high blood pressure (hypertension).


Q: How long does it typically take for Espiro to start working?

A: Official clinical studies suggest that the maximum blood pressure-lowering effect is often seen within four weeks after starting Espiro treatment. The timing of effects may vary based on the condition being treated.


Q: Does Espiro offer immediate relief or is it a long-term control medicine?

A: Official information classifies Espiro as a medication intended for the long-term management of chronic conditions, such as heart failure and hypertension. It is not intended to provide immediate or rapid relief for acute symptoms.


Q: Is it better to take Espiro in the morning or evening?

A: Regulatory guidance states that Espiro is typically taken once daily and can be taken with or without food. The most important factor is maintaining a consistent approach, which means taking it at the same time each day.


Q: How quickly do people generally notice an improvement after starting Espiro?

A: While the blood pressure-lowering effect is usually seen within four weeks, the timing of when a person notices subjective improvement can vary and is not specifically defined in the product information.


Q: Does Espiro commonly cause weight gain?

A: Official regulatory documents summarizing clinical trials for Espiro did not report weight gain as a common or uncommon adverse reaction.


Q: Can Espiro affect my sleep?

A: Sleep issues, such as insomnia or excessive drowsiness, are not listed as common or uncommon adverse reactions in the official clinical trial data for Espiro.


Q: Why do some people say Espiro makes them feel anxious or jittery?

A: While nervousness is listed as a potential adverse reaction in regulatory reports, anxiety or a jittery feeling are not specifically identified as common or uncommon side effects in the clinical trial data for Espiro.


Q: Is it normal to feel dizzy after starting Espiro?

A: Regulatory documents list dizziness as a common adverse reaction, especially when Espiro is used for high blood pressure. This effect is often noted when initiating treatment.


Q: Does Espiro make my heart rate faster?

A: A fast or irregular heartbeat is not listed as a common or uncommon side effect in regulatory documents. However, a fast or irregular heartbeat can be a sign of hyperkalemia (high potassium levels), which is a serious adverse reaction.


Q: Does Espiro have a known effect on blood pressure?

A: Yes, one of the main intended effects of Espiro is to lower high blood pressure (hypertension). Low blood pressure (hypotension) has also been reported as an uncommon adverse reaction in clinical studies.


Q: What is the difference between the Espiro tablet and the Espiro capsule (if applicable)?

A: According to official product information, Espiro’s active ingredient, Eplerenone, is manufactured as an oral film-coated tablet. An official capsule formulation is not listed as an approved dosage form.


Q: What is the maximum length of time Espiro is recommended to be used?

A: The official product information does not specify a maximum duration for Espiro use. Since it is prescribed for the long-term management of chronic conditions like heart failure and hypertension, continuous use is often necessary.


Q: How does Espiro interact with caffeine?

A: The drug’s official labeling notes specific interactions with certain medications, foods (like grapefruit), and herbal products (like St. John’s Wort). However, it does not mention a specific interaction between Espiro and caffeine.


Q: Is it common for doctors to prescribe Espiro long-term?

A: Yes, Espiro is indicated for the treatment of chronic conditions such as heart failure and high blood pressure. These conditions generally require continuous, long-term medication use for effective management.


Q: What are some less common side effects of Espiro?

A: In addition to the common side effects, regulatory documents note that less common adverse reactions reported in clinical trials include symptoms such as abnormal vaginal bleeding, breast pain, chills, and cloudy urine.


Q: Does Espiro cause dry mouth or throat?

A: Dry mouth or throat are not listed as common or uncommon adverse reactions in the clinical trial data found in the official product labeling for Espiro.


Q: Are there any dietary restrictions while on Espiro?

A: Yes, official patient information advises avoiding potassium-containing salt substitutes and grapefruit products. These substances can affect the way the medication works and potentially increase its concentration in the blood.


Q: Can I use Espiro if I have benign prostatic hypertrophy (BPH)?

A: Espiro is not indicated for the treatment of BPH. While it may have some effects on the androgen receptor, the regulatory documents do not list a specific caution or contraindication regarding BPH.


Q: Is Espiro safe for use in children?

A: Espiro is not approved for the treatment of high blood pressure (hypertension) in children. Use in the pediatric population for other indications requires specialized professional assessment and is highly restricted.

How should Espiro be stored and disposed of?

Espiro (Eplerenone) tablets must be stored at Controlled Room Temperature, which is officially defined as 20 C to 25 C (68 F to 77 F). The regulatory labeling permits brief temperature excursions between 15 C and 30 C (59 F and 86 F).

  • Protection: The tablets must be kept in the original, tightly closed container and protected from excess heat and moisture; they should not be frozen or stored above 30 C.
  • Child Safety: The medication must be kept out of the sight and reach of children and safety caps must be locked.
  • Disposal: Unused or expired Espiro must be discarded according to local regulations or a pharmaceutical drug take-back program. If a take-back program is unavailable, non-flushable medicines should be mixed with an undesirable substance before being sealed in a container and placed in household trash, preventing environmental discharge.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Espiro found in:

A-Z Index: